News

1 day ago

iQure Pharma Receives Approval for iQ-007 Phase 1 First in Human Study

Princeton, NJ, March 12, 2025 ─ iQure Pharma Inc. (iQure), a biotechnology company focused on the development of novel therapies for...

Jan 23

iQure Pharma’s iQ-007 Receives FDA Orphan Drug Designation for Dravet’s Syndrome

Princeton, NJ, January 23, 2025 ─ iQure Pharma Inc. (iQure), a biotechnology company focused on the development of novel therapies for...

Jan 7

iQure Pharma Secures $4M Funding – Advancing Phase 1 Clinical Trial for iQ-007

Princeton, NJ, January 07, 2025 ─ iQure Pharma Inc. (iQure), a biotechnology company focused on the development of novel therapies for...

Jun 20, 2024

iQ-007 Zebrafish Screening Reveals Positive Results in Other Neurodegenerative Diseases

Princeton, NJ, June 21 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech company dedicated to the development of new epilepsy...

Mar 19, 2024

Initial iQ-007 IND-Enabling Tox Results Accelerate Prep for First in Human Phase 1 Study

Princeton, NJ, March 19, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-007, a novel...

Jan 23, 2024

iQure Pharma Awarded Its First Patent for iQ-008, a Novel Analgesic Compound to Treat Neuropathic Pain

Princeton, NJ, January 23, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-008, a novel...

Nov 28, 2023

iQure Pharma Announces Impressive Second Close of Oversubscribed Series A Financing

Princeton, NJ, 28 November, 2023 ─ iQure Pharma Inc, (iQure) a trailblazing pre-clinical drug discovery company focusing on central...

Oct 11, 2023

iQure Pharma Secures Funding from Ventura BioMed Investors and OKG Capital

Princeton, NJ, October 11, 2023 ─ iQure Pharma Inc. (iQure), a CNS company dedicated to the development of new epilepsy and pain...

Sep 5, 2023

iQ-007 Accepted into Prestigious NIH Preclinical Screening Platform for Pain (PSPP) Program

Princeton, NJ, September 5, 2023 ─ iQure Pharma Inc. (iQure), a company dedicated to the development of new epilepsy and pain management...

Aug 21, 2023

iQure Pharma’s iQ-007 Completes Critical Go/No Go Criteria - September Start for MTD & GLP Tox Study

Princeton, NJ, August 21, 2023 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has completed its key go/no go criteria enabling...

Jul 5, 2023

iQure Pharma Awarded Second Patent for iQ-007, Novel Therapy to Treat Neuropathic Pain & Epilepsy

Princeton, NJ, July 6, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has been awarded a second patent for...

May 15, 2023

iQure Pharma’s iQ-007 Achieves Critical Pre-Clinical Milestone

Princeton, NJ, May 15, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has achieved a major milestone by completing...

Feb 24, 2023

iQure Pharma’s iQ-007 & iQ-008 Compounds Continue to Deliver Promising Results

Princeton, NJ, February 24, 2023 ─ iQure Pharma Inc. (iQure), a US-based biotech company, is making significant progress in the...

Nov 15, 2022

iQ-007 shows no abuse potential in FDA recommended panel of tests

Princeton, NJ, November 15, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has confirmed through preclinical screenings...

Sep 18, 2022

iQure Pharma Selected to Join NYU Stern Endless Frontier Labs (EFL) 2022-2023 Life Sciences Track

iQure Pharma is one of 25 companies invited to join the NYU Stern School of Business Endless Frontier Labs 2022-2023 cohort dedicated to...

Sep 8, 2022

iQ-007 Considered as First-in-Class Therapeutic Agent in Prestigious Journal of Medicinal Chemistry

International team of scientists share research that demonstrates the effectiveness of iQ-007 and its unique mechanism of action...

Mar 15, 2022

iQure Pharma Meets Lipinski’s (Pfizer’s) Rule of Five with Analgesic Compound for Neuropathic Pain

DELAWARE, March 15, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has confirmed through preclinical screenings that...

Nov 5, 2021

Novel and promising mechanism of action for new neuropathic pain candidate iQ-007 confirmed

Delaware – November 2021, iQure Pharma Inc. (iQure), a company dedicated to the development of new pain management therapeutics, can...

May 25, 2021

iQ-008 Accepted into NIH Preclinical Screening Platform for Pain (PSPP)

Delaware – May 2021, iQure Pharma Inc. (iQure), a company dedicated to the development of new pain management therapeutics, is proud to...

Sep 22, 2020

Preliminary Subchronic Toxicology Study Results Indicate iQ-007 Has Favorable Safety Profile

Delaware – September 2020.iQure Pharma Inc. (iQure), a company dedicated to preclinical and early clinical development of new...

JPM Week

No Abuse